NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq: NRXP) initiated a first commercial GMP manufacturing order for a preservative-free ketamine product ahead of expected GDUFA approval in Summer 2026. The program follows stability from 3 registration batches and a third-party GMP audit; pre-approval inspection readiness is reported.
Manufacturing uses a blow-fill-seal process with >10-fold throughput versus traditional sterile bottling. Company named Glenn Tyson as Chief Commercial Officer and cites ASHP shortage data (April 7, 2026) to underline domestic supply need.
Positive
- First US-made preservative-free ketamine presentation
- Initiated first commercial GMP manufacturing order
- Stability demonstrated in 3 registration batches
- Blow-fill-seal process yields >10x throughput vs traditional bottling
- Named Glenn Tyson as Chief Commercial Officer
Negative
- Approval pending under GDUFA (expected Summer 2026)
- Product supply currently tied to a single US-based manufacturer
- Pre-approval inspection of facility is not yet completed
News Market Reaction – NRXP
In the May 5 session, NRXP gained 1.33%, reflecting a mild positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Regulatory feedback | Positive | +1.7% | Positive FDA Discipline Review Letter on preservative-free ketamine ANDA with minor changes. |
| Apr 20 | Policy support | Positive | +25.5% | Presidential order to accelerate psychedelic approvals and NRX-100 NDA pathway highlighted. |
| Apr 15 | R&D initiative | Positive | +0.8% | Launch of NRx Defense Systems for combined neuroplastic therapy and TMS applications. |
| Apr 13 | Management hire | Positive | +2.7% | Appointment of first Chief Commercial Officer to prepare for ketamine and NRX‑101 launches. |
| Apr 06 | Labeling alignment | Positive | +2.3% | FDA preliminary labeling alignment for preservative‑free ketamine ANDA with only minor comments. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news on preservative-free ketamine and regulatory progress has generally led to positive price reactions, suggesting the stock has tended to respond favorably to similar development and commercialization updates.
Over the past month, NRx has repeatedly advanced its preservative‑free ketamine program and broader neuroplastic pipeline. On Apr 6 and Apr 22, FDA Office of Generic Drugs letters and labeling alignment supported an anticipated Summer 2026 GDUFA decision, with modest gains. A Apr 20 policy-related psychedelic headline saw a larger 25.49% move. Management strengthened commercialization on Apr 13 by appointing a Chief Commercial Officer. Today’s manufacturing initiation builds directly on those regulatory and commercial milestones, moving the asset closer to launch readiness.
Key Terms
GMP technical
pre-approval inspection regulatory
blow-fill-seal technical
Generic Drug User Fee Act regulatory
Benzethonium Chloride medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Based on FDA Office of Generic Drugs guidance previously announced, NRx has transmitted an initial GMP manufacturing order to its US-based manufacturer.
- NRx has completed confirmatory GMP audits of manufacture and is prepared for pre-approval inspection.
- Initial manufacture rate is sufficient to support significant market penetration in first year sales and can be readily scaled based on blow-fill-seal manufacturing process.
WILMINGTON, Del., May 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces initiation of a first commercial manufacturing order of its preservative free ketamine product in anticipation of approval under the Generic Drug User Fee Act in Summer 2026. The order is based on stability observed in more than 3 manufactured registration batches and the Company’s successful third-party audit of the manufacturing facility.
The Company expects that the initial manufacturing pace will be sufficient to support initial substantial yearly revenues and notes the ability to rapidly scale manufacturing as demand grows. The Company recently announced the appointment of Mr. Glenn Tyson as its Chief Commercial Officer and is in the process of retaining a full commercial team.
The NRx product is the first US-manufactured preservative-free ketamine presentation. Manufacturing is accomplished via a blow-fill-seal process that achieves more than 10-fold higher manufacturing throughput than traditional sterile bottling techniques that rely on glass vials and traditional seals.
NRx’s presentation of ketamine differs from existing products in that it does not contain a known toxic preservative, Benzethonium Chloride. This preservative is no longer allowed to be included in new drugs and according to FDA policy cannot even be included in hand cleansers and topical antiseptics.
As of April 7, 2026, sterile intravenous ketamine remains listed on the American Society of Health-System Pharmacists (ASHP) national drug shortage database. ASHP reports ongoing supply constraints across multiple manufacturers, including product discontinuations, back orders, and reliance on short-dated inventory for certain ketamine injection presentations, particularly higher-concentration vials commonly used in hospital and outpatient settings. These recurring disruptions have periodically required healthcare providers to adjust sourcing and clinical use, highlighting the need for additional reliable, domestically manufactured ketamine supply.
“NRx thanks its manufacturing partner for the care and support that has been invested in this project and looks forward to being able to serve Americans with a safe and convenient US-made ketamine product. We hope to alleviate the supply shortages that have frequently been reported in association with sterile ketamine,” said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
